Research Article
Development of Monoclonal Antibody-Based EIA for Tetranor-PGDM which Reflects PGD2 Production in the Body
Table 1
Precision of the proposed EIA for tetranor-PGDM measurement at different concentration levels.
| Concentration (ng/mL) | Mean recoveries (%) | Spiked | Mean | SD | CV (%) |
| Within-run () | | | | | 1.024 | 1.14 | ± | 0.07 | 6.0 | 111.7 | 2.56 | 2.29 | ± | 0.11 | 4.8 | 89.4 | 6.4 | 6.19 | ± | 0.24 | 3.9 | 96.6 | Between-day () | | | | | | 1.024 | 1.10 | ± | 0.11 | 10.4 | 107.6 | 2.56 | 2.45 | ± | 0.14 | 5.7 | 95.5 | 6.4 | 6.25 | ± | 0.41 | 6.6 | 97.7 |
|
|